Pharmacies may only dispense drugs for 90 days

1 April 2020 - As of today, April 1, pharmacies cannot deliver a larger amount of drug than the amount ...

Read more →

Health economic assessment of Keytruda in combination with Inlyta in kidney cell cancer

31 March 2020 - TLV has developed a health economic knowledge base for the regions for combination treatment with the drugs ...

Read more →

COVID-19 and processing times

23 March 2020 - At present, TLV's operations continue as usual.  ...

Read more →

Erlotinib new exchange groups

13 March 2020 - As of April, erlotinib is included as an exchange group on the list of goods for ...

Read more →

TLV has decided to reconsider subsidy restrictions for several drugs

16 March 2020 - TLV starts two different re-examination of subsidy restrictions for certain drugs and drug groups with the ...

Read more →

Health economic assessment of Kadcyla in the treatment of HER2 positive, early breast cancer

6 March 2020 - TLV has developed a health economic knowledge base for the regions for the drug Kadcyla (trastuzumab emtansine).  ...

Read more →

TLV has decided on a policy for patient participation

21 February 2020 - TLV has taken another step in developing patient participation by developing a policy.  ...

Read more →

New and removed exchange groups

14 February 2020 - An exchange group is a group of drugs that the Swedish Medicines Agency has judged to be ...

Read more →

Withdrawal from the drug benefits on 1 March 2020

12 February 2020 - Aprovel, Differin and Plavix are among the medicines that are withdrawn from the drug benefits at the ...

Read more →

Mayzent is granted temporary subsidy

5 February 2020 - The Dental and Pharmaceutical Benefits Agency has decided that Mayzent, 0.25 and 2 mg film-coated tablet ...

Read more →

TLV is reviewing the subsidy of factor VIII drugs with side agreements

28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves ...

Read more →

Withdrawal from the drug benefits on 1 February 2020

16 January 2020 - Iressa, Procoralan, Skinoren Cream, Vesicare and Reyataz are among the medicines that are withdrawn from the drug ...

Read more →

TLV has decided to reconsider the subsidy for Xeljanz

14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the ...

Read more →

TLV has decided to reconsider the subsidy for Olumiant

14 January 2020 - When TLV decided that Olumiant should be included in the high-cost protection, this was justified by the ...

Read more →

Health economic assessment of Kyprolis in combination with Revlimid and dexamethasone

17 December 2019 - TLV has developed a new health economic knowledge base for the regions of the drug Kyprolis ...

Read more →